Novo Nordisk nabs priority review voucher for $110M from Marinus as the biotech preps first drug launch

Max Gelman

Senior Editor

When Marinus Pharmaceuticals completed its turnaround and finally pushed its sole drug across the FDA finish line, the company noted it would sell the priority …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novo Nordisk nabs priority review voucher for $110M from Marinus as the biotech preps first drug launch

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Patient dies in Neurogene's Rett syndrome study

Sanofi introduces new 340B payment model — report

No­vo Nordisk nabs pri­or­i­ty re­view vouch­er for $110M from Mar­i­nus as the biotech preps first drug launch

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

Novo Nordisk nabs priority review voucher for $110M from Marinus as the biotech preps first drug launch

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Patient dies in Neurogene's Rett syndrome study

Sanofi introduces new 340B payment model — report